Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Non-Current Debt (2017 - 2024)

Organogenesis Holdings has reported Non-Current Debt over the past 8 years, most recently at $56.2 million for Q3 2024.

  • For Q3 2024, Non-Current Debt fell 9.6% year-over-year to $56.2 million; the TTM value through Sep 2024 reached $56.2 million, down 9.6%, while the annual FY2023 figure was $60.7 million, 8.28% down from the prior year.
  • Non-Current Debt for Q3 2024 was $56.2 million at Organogenesis Holdings, down from $57.7 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $71.7 million in Q3 2021 and troughed at $10.0 million in Q1 2020.
  • A 5-year average of $52.2 million and a median of $60.7 million in 2023 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: tumbled 79.85% in 2020 and later surged 607.69% in 2021.
  • Year by year, Non-Current Debt stood at $10.0 million in 2020, then surged by 607.69% to $70.8 million in 2021, then decreased by 6.41% to $66.2 million in 2022, then fell by 8.28% to $60.7 million in 2023, then fell by 7.56% to $56.2 million in 2024.
  • Business Quant data shows Non-Current Debt for ORGO at $56.2 million in Q3 2024, $57.7 million in Q2 2024, and $59.4 million in Q1 2024.